Neurological adverse events in patients receiving anti-TNF therapy: A prospective imaging and electrophysiological study

Arthritis Research and Therapy

Volumn 16, Issue 3, 2014, Pages

  Kaltsonoudis, Evripidis ^a   Zikou, Anastasia K ^a   Voulgari, Paraskevi V ^a   Konitsiotis, Spyridon ^a   Argyropoulou, Maria I ^a   Drosos, Alexandros A ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; AUTOANTIBODY; IMMUNOGLOBULIN G; INFLIXIMAB; MONOCLONAL ANTIBODY; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; ETANERCEPT; GABAPENTIN; MEPREDNISONE;

ADULT; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; BRAIN; CERVICAL SPINE; CHEMICALLY INDUCED; FEMALE; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; NEUROLOGIC DISEASE; NEUROPHYSIOLOGICAL MONITORING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PROCEDURES; PROSPECTIVE STUDY; RADIOGRAPHY; REPRODUCIBILITY; SPONDYLARTHROPATHIES; SPONDYLITIS, ANKYLOSING; ADVERSE DRUG REACTION; ANKYLOSING SPONDYLITIS; ARTICLE; DENERVATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPHAGIA; ELECTROMYOGRAM; EYE PAIN; FACIAL NERVE PARALYSIS; MAJOR CLINICAL STUDY; NEUROLOGIC EXAMINATION; OPTIC NEURITIS; PARESTHESIA; PERONEUS NERVE PARALYSIS; PHYSICAL EXAMINATION; PSORIATIC ARTHRITIS; PTOSIS; RHEUMATOID ARTHRITIS; SPEECH DISORDER;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BRAIN; CERVICAL VERTEBRAE; FEMALE; HUMANS; IMMUNOGLOBULIN G; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; NEUROPHYSIOLOGICAL MONITORING; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; REPRODUCIBILITY OF RESULTS; SPONDYLARTHROPATHIES; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84902301081     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4582     Document Type: Article

References (51)

1. Lin J, Ziring D, Desai S, Kim S, Wong M, Korin Y, Braun J, Reed E, Gjertson D, Singh RR. TNFalpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol 2008, 126:13-30.
2. Voulgari PV, Alamanos Y, Nikas SN, Bougias DV, Temekonidis TI, Drosos AA. Infliximab therapy in established rheumatoid arthritis: an observational study. Am J Med 2005, 118:515-520.
3. Temekonidis TI, Alamanos Y, Nikas SN, Bougias DV, Georgiadis AN, Voulgari PV, Drosos AA. Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study. Ann Rheum Dis 2003, 62:1218-1220.
4. Voulgari PV, Venetsanopoulou AI, Exarchou SA, Alamanos Y, Tsifetaki N, Drosos AA. Sustained clinical response and high infliximab survival in psoriatic arthritis patients: a 3-year long-term study. Semin Arthritis Rheum 2008, 37:293-298.
5. Saougou I, Markatseli TE, Voulgari PV, Drosos AA. Maintained clinical response of infliximab treatment in ankylosing spondylitis: a 6-year long-term study. Joint Bone Spine 2010, 77:325-329.
6. Saougou I, Markatseli TE, Papagoras C, Voulgari PV, Alamanos Y, Drosos AA. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study. Semin Arthritis Rheum 2011, 40:398-406.
7. Markatseli TE, Alamanos Y, Saougou I, Voulgari PV, Drosos AA. Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study. Clin Exp Rheumatol 2012, 30:31-38.
8. Flouri I, Markatseli TE, Voulgari PV, Boki KA, Papadopoulos I, Settas L, Zisopoulos D, Skopouli FN, Iliopoulos A, Bertsias GK, Geborek P, Drosos AA, Boumpas DT, Sidiropoulos P. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival. Semin Arthritis Rheum 2014, 43:447-457.
9. Borchers AT, Leibushor N, Cheema GS, Naguwa SM, Gershwin ME. Immune-mediated adverse effects of biologicals used in the treatment of rheumatic diseases. J Autoimmun 2011, 37:273-288.
10. Nikas SN, Voulgari PV, Drosos AA. Urticaria and angiedema-like skin reactions in a patient treated with adalimumab. Clin Rheumatol 2007, 26:787-788.
11. Voulgari PV, Markatseli TE, Exarchou SA, Zioga A, Drosos AA. Granuloma annulare induced by anti-tumour necrosis factor therapy. Ann Rheum Dis 2008, 67:567-570.
12. Exarchou SA, Voulgari PV, Markatseli TE, Zioga A, Drosos AA. Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors. Scand J Rheumatol 2009, 38:328-331.
13. Fiorino G, Danese S, Pariente B, Allez M. Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-α agents. Autoimmun Rev 2013, 13:15-19.
14. van Oosten BW, Barkhof F, Truyen L, Boringa JB, Bertelsmann FW, von Blomberg BM, Woody JN, Hartung HP, Polman CH. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996, 47:1531-1534.
15. Sicotte NL, Voskuhl RR. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 2001, 57:1885-1888.
16. Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, Richert JR, Siegel JN. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001, 44:2862-2869.
17. Robinson WH, Genovese MC, Moreland LW. Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?. Arthritis Rheum 2001, 44:1977-1983.
18. Cisternas M, Gutiérrez M, Jacobelli S. Successful rechallenge with anti-tumor necrosis factor alpha for psoriatic arthritis after development of demyelinating nervous system disease during initial treatment: comment on the article by Mohan et al. Arthritis Rheum 2002, 46:3107-3108.
19. Titelbaum DS, Degenhardt A, Kinkel RP. Anti-tumor necrosis factor alpha-associated multiple sclerosis. AJNR Am J Neuroradiol 2005, 26:1548-1550.
20. Ruiz-Jimeno T, Carvajal A, Mata C, Aurrecoechea E. Demyelinating disease in a patient with psoriatic arthritis and family history of multiple sclerosis treated with infliximab. J Rheumatol 2006, 33:1457-1458.
21. Dubcenco E, Ottaway CA, Chen DL, Baker JP. Neurological symptoms suggestive of demyelination in Crohn's disease after infliximab therapy. Eur J Gastroenterol Hepatol 2006, 18:565-566.
22. Toussirot E, Pertuiset E, Martin A, Melac-Ducamp S, Alcalay M, Grardel B, Seror P, Perdriger A, Wendling D, Mulleman D, Beraneck L, Mariette X, . Club Rheumatismes et Inflammation Association of rheumatoid arthritis with multiple sclerosis: report of 14 cases and discussion of its significance. J Rheumatol 2006, 33:1027-1028. Club Rheumatismes et Inflammation.
23. Magnano MD, Robinson WH, Genovese MC. Demyelination and inhibition of tumor necrosis factor (TNF). Clin Exp Rheumatol 2004, 22:S134-S140.
24. Mejico LJ. Infliximab-associated retrobulbar optic neuritis. Arch Ophthalmol 2004, 122:793-794.
25. Shin IS, Baer AN, Kwon HJ, Papadopoulos EJ, Siegel JN. Guillain-Barré and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy. Arthritis Rheum 2006, 54:1429-1434.
26. Gomez-Gallego M, Meca-Lallana J, Fernandez-Barreiro A. Multiple sclerosis onset during etanercept treatment. Eur Neurol 2008, 59:91-93.
27. Winkelmann A, Patejdl R, Wagner S, Benecke R, Zettl UK. Cerebral MRI lesions and anti-tumor necrosis factor-alpha therapy. J Neurol 2008, 255:109-114.
28. Mignarri A, Dotti MT, Battisti C, Vallone I, Federico A. Occurrence of ankylosing spondylitis and multiple sclerosis-like syndrome in a HLA-B27 positive patient. Neurol Sci 2009, 30:329-332.
29. Pfueller CF, Seipelt E, Zipp F, Paul F. Multiple sclerosis following etanercept treatment for ankylosing spondylitis. Scand J Rheumatol 2008, 37:397-399.
30. Lozeron P, Denier C, Lacroix C, Adams D. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. Arch Neurol 2009, 66:490-497.
31. Fromont A, De Seze J, Fleury MC, Maillefert JF, Moreau T. Inflammatory demyelinating events following treatment with anti-tumor necrosis factor. Cytokine 2009, 45:55-57.
32. Bernatsky S, Renoux C, Suissa S. Demyelinating events in rheumatoid arthritis after drug exposures. Ann Rheum Dis 2010, 69:1691-1693.
33. Ramos-Casals M, Roberto-Perez A, Diaz-Lagares C, Cuadrado MJ, Khamashta MA, . BIOGEAS Study Group Autoimmune diseases induced by biological agents: a double-edged sword?. Autoimmun Rev 2010, 9:188-193. BIOGEAS Study Group.
34. Solomon AJ, Spain RI, Kruer MC, Bourdette D. Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors. Mult Scler 2011, 17:1472-1487.
35. Caminero A, Comabella M, Montalban X. Tumor necrosis factor alpha (TNF-α), anti-TNF-α and demyelination revisited: an ongoing story. J Neuroimmunol 2011, 234:1-6.
36. Nozaki K, Silver RM, Stickler DE, Abou-Fayssal NG, Giglio P, Kamen DL, Daniel R, Judson MA. Neurological deficits during treatment with tumor necrosis factor-alpha antagonists. Am J Med Sci 2011, 342:352-355.
37. Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies. Arthritis Rheum 2012, 64:3043-3051.
38. Fernández-Espartero MC, Pérez-Zafrilla B, Naranjo A, Esteban C, Ortiz AM, Gómez-Reino JJ, Carmona L, . BIOBADASER Study Group Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review. Semin Arthritis Rheum 2011, 40:330-337. BIOBADASER Study Group.
39. Bosch X, Saiz A, Ramos-Casals M, . BIOGEAS Study Group Monoclonal antibody therapy-associated neurological disorders. Nat Rev Neurol 2011, 7:165-172. BIOGEAS Study Group.
40. Faillace C, de Almeida JR, de Carvalho JF. Optic neuritis after infliximab therapy. Rheumatol Int 2013, 33:1101-1103.
41. Andreadou E, Kemanetzoglou E, Brokalaki C, Evangelopoulos ME, Kilidireas C, Rombos A, Stamboulis E. Demyelinating disease following anti-TNFa treatment: a causal or coincidental association? Report of four cases and review of the literature. Case Rep Neurol Med 2013, 2013:671935.
42. Tehlirian CV, Bathon JM. Rheumatoid Arthritis. Clinical and Laboratory Manifestations. Chapter 6. Primer on the Rheumatic Diseases 2008, 114-121. New York, USA: Springer, Klippel JH, Stone JH, Crofford LJ, White PH, 13.
43. van der Heijde D. Ankylosing Spondylitis Clinical Features. Chapter 9. Primer on the Rheumatic Diseases 2008, 193-199. New York, USA: Springer, Klippel JH, Stone JH, Crofford LJ, White PH, 13.
44. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
45. Rudwaleit M, van der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J, Braun J, Chou CT, Collantes-Estevez E, Dougados M, Huang F, Gu J, Khan MA, Kirazli Y, Maksymowych WP, Mielants H, Sørensen IJ, Ozgocmen S, Roussou E, Valle-Oñate R, Weber U, Wei J, Sieper J. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009, 68:777-783.
46. Okuda DT, Mowry EM, Beheshtian A, Waubant E, Baranzini SE, Goodin DS, Hauser SL, Pelletier D. Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology 2009, 72:800-805.
47. Kaltsonoudis E, Voulgari PV, Konitsiotis S, Drosos AA. Demyelination and other neurological adverse events after anti-TNF therapy. Autoimmun Rev 2014, 13:54-58.
48. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000, 343:938-952.
49. van Boxel-Dezaire AH, Hoff SC, van Oosten BW, Verweij CL, Dräger AM, Adèr HJ, van Houwelingen JC, Barkhof F, Polman CH, Nagelkerken L. Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Ann Neurol 1999, 45:695-703.
50. Prinz JC. Autoimmune-like syndromes during TNF blockade: does infection have a role?. Nat Rev Rheumatol 2011, 7:429-434.
51. Midgard R, Grønning M, Riise T, Kvåle G, Nyland H. Multiple sclerosis and chronic inflammatory diseases. A case-control study. Acta Neurol Scand 1996, 93:322-328.